share_log

Altimmune | 4: Statement of changes in beneficial ownership of securities-Officer Harris Matthew Scott

Altimmune | 4: Statement of changes in beneficial ownership of securities-Officer Harris Matthew Scott

Altimmune | 4：持股變動聲明-高管 Harris Matthew Scott
美股sec公告 ·  08/02 05:41
牛牛AI助理已提取核心訊息
Altimmune's Chief Medical Officer, Harris Matthew Scott, completed a purchase of 1,486 shares of the company's common stock on July 31, 2024. The transaction was carried out at a price of $5.41 per share, resulting in a total investment of $8,039.66. Following this acquisition, Harris now directly holds a total of 55,119 shares in Altimmune. The transaction reflects a direct ownership in the securities and is categorized as a grant, award, or other acquisition as per the transaction code 'A'.
Altimmune's Chief Medical Officer, Harris Matthew Scott, completed a purchase of 1,486 shares of the company's common stock on July 31, 2024. The transaction was carried out at a price of $5.41 per share, resulting in a total investment of $8,039.66. Following this acquisition, Harris now directly holds a total of 55,119 shares in Altimmune. The transaction reflects a direct ownership in the securities and is categorized as a grant, award, or other acquisition as per the transaction code 'A'.
2024年7月31日，Altimmune的首席醫療官賀錦麗·馬修·斯科特以每股5.41美元的價格購買了1,486股公司普通股，總投資額爲8,039.66美元。此次交易使賀錦麗在Altimmune直接持有55,119股股份。該交易反映了對證券的直接持有，並被歸類爲授權、獎勵或其他收購的交易代碼'A'。
2024年7月31日，Altimmune的首席醫療官賀錦麗·馬修·斯科特以每股5.41美元的價格購買了1,486股公司普通股，總投資額爲8,039.66美元。此次交易使賀錦麗在Altimmune直接持有55,119股股份。該交易反映了對證券的直接持有，並被歸類爲授權、獎勵或其他收購的交易代碼'A'。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。